Hutchison Whampoa declares third-generation BTK inhibitor

On July 27, the CDE official website showed that Hutchison Whampoa submitted a clinical application for the BTK inhibitor HMPL-760 capsule and was accepted
.

According to official information, HMPL-760 is a third-generation BTK inhibitor with the ability to reversibly and non-covalently bind wild-type and C481S mutant BTK
.
In animal experiments, HMPL-760 has a stronger binding force than ibrutinib and ARQ-531, and has the potential to be used in combination with the PI3Kδ inhibitor HMPL-689 and the CD47 monoclonal antibody HMPL-A83

Now in China, BTK inhibitors can be called PD-1 in the field of chemical drugs, and 18 domestic projects and 8 imported drug projects have entered the clinical stage
.
In the first half of 2021 alone, 4 new projects were approved for clinical trials, and 3 new projects started clinical trials

However, there are few domestic R&D projects for the third-generation BTK inhibitors.